Introduction: onychomycosis is defined as a fungal infection of the nails. They represent the main cause of onychopathy. They constitute a public health problem because of their increased prevalence in the world ranging between 20 to 30%. However, they remain under documented in Madagascar. This study was conducted in order to determine the mycological profile of onychomycosis diagnosed in the Parasitology Mycology laboratory of CHU-JRA.
Methods: a descriptive retrospective study was taken over a 13-year period from June 2005 to December 2018. The data presenting onychomycosis on the mycological outcome register were included in the study. Results showing the presence of fungi on direct examination and / or culture were considered positive.
Results: during the study period, a prevalence of 17.75% (180/1014) was observed. The age of our patients ranged from 3 to 76 years. Women were the most affected in 68.34% (n = 123) with a sex ratio of 0.46. Onychomycosis was localized in 64.65% of the fingers (n = 128). Simultaneous involvement of the hands and feet was found in 10% of the cases (n = 18). Candida albicans (C. albicans) was the most isolated in 33.03% (n = 71) of cases, followed by other species of Candida (24.65%, n = 53) and Trichophyton spp (9.3%, n=17). Mixed infections associating dermatophytes, Yeasts and molds were found in 23.33% (n = 42) of the cases.
Conclusion: this is the first investigation dealing with onychomycosis in Madagascar. These data may be useful for future research and in the development of preventive and educational strategies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720234 | PMC |
http://dx.doi.org/10.11604/pamj.2021.40.176.25216 | DOI Listing |
J Fungi (Basel)
January 2025
Mediprobe Research Inc., London, ON N5X 2P1, Canada.
We find the comment on the article titled "Diabetic Foot and Fungal Infections: Etiology and Management from a Dermatologic Perspective" informative and wish to thank the authors for their added insight on this complex topic [...
View Article and Find Full Text PDFJ Fungi (Basel)
January 2025
DYNAMYC UR 7380, Faculté de Santé, Université Paris-Est Créteil (UPEC), 94010 Créteil, France.
We read the review by Gupta et al [...
View Article and Find Full Text PDFIndian Dermatol Online J
December 2024
Department of Clinical Research, CUTIS Academy of Cutaneous Sciences, Bengaluru, Karnataka, India.
Background: Laser therapy has emerged as an innovative approach for managing various nail conditions, offering precise targeting, minimal invasiveness, and favorable safety profiles. This review analyzes the literature on laser therapy for nail indications, encompassing onychomycosis, nail psoriasis, nail warts, ingrown toenails, onychodystrophy, nail pigmentation disorders, and nail tumors.
Methods: PubMed and Google Scholar databases were searched to identify articles on laser therapy using specific key terms related to nail conditions (e.
Indian Dermatol Online J
December 2024
Financial Research and Executive Insights, Everest Group, Gurugram, Haryana, India.
Background: Artificial intelligence (AI) is revolutionizing healthcare by enabling systems to perform tasks traditionally requiring human intelligence. In healthcare, AI encompasses various subfields, including machine learning, deep learning, natural language processing, and expert systems. In the specific domain of onychology, AI presents a promising avenue for diagnosing nail disorders, analyzing intricate patterns, and improving diagnostic accuracy.
View Article and Find Full Text PDFInfect Dis Rep
January 2025
Mediprobe Research Inc., London, ON N5X 2P1, Canada.
Background/objectives: In an 18- to 24-month Treatment Phase with once-daily efinaconazole 10% solution, subjects with onychomycosis showed an increased rate of cure at Month 24 versus the phase III trials. In order to further improve efficacy, we initiated an extended intermittent efinaconazole Maintenance Phase with use 2-3 times weekly for an additional 24 months from Month 24 to Month 48. These are the first data presented for a 48-month efinaconazole use period.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!